U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07487402) titled 'Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma' on March 17.
Brief Summary: A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent/Metastatic Hepatocellular Carcinoma.
Study Start Date: March 30
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma (HCC)
Intervention:
DRUG: Metabolically Armed GPC3 CAR-T cells
Each subject receive metabolically armed GPC3 CAR- T cells by intravenous infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Zhejian...